Bipolar Disorder (Manic Depression) – Pipeline Review, 2024

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

1.1. ReportOverview

2. Bipolar Disorder (Manic Depression) - Overview

3. Executive Summary

4. Bipolar Disorder (Manic Depression): Pipeline Assessment

4.1. By Stage of Development

4.2. By Route ofAdministration

4.3. By DrugClass

4.4. By MoleculeType

4.5. By TherapyArea / Indication

4.6. By DrugTarget

4.7. By Sponsor

5. Bipolar Disorder (Manic Depression): Company & Drug Profiles

5.1. ClinicalStage

5.1.1. NRX-101 – NeuroRx, Inc.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. FK949E – Astellas Pharma Inc.

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. Lithium – Roxane Laboratories

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Bipolar Disorder (Manic Depression): An Overview on Dormant &Discontinued Pipeline Candidates

6.1. Overview

6.2. ProductDescription

6.3. Reason forDiscontinuation

7. Bipolar Disorder (Manic Depression): Additional Key Insight

7.1.Epidemiology Overview: Bipolar Disorder

7.2. CurrentMarket Scenario: Bipolar Disorder Therapeutics

8. Bipolar Disorder (Manic Depression): News, Press Releases andConference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.